Feeds

HIV vaccine safe for Phase II human trials

Canadian university claim no adverse effects from first tests

SANS - Survey on application security programs

Researchers from the Schulich School of Medicine & Dentistry at Canada's University of Western Ontario have issued a statement saying the first phase of clinical trials of an HIV vaccine have produced “no adverse effects observed including local reactions, signs/symptoms and laboratory toxicities”.

The Reg understands the trial of the vaccine, dubbed'SAV001-H' involved only 40 patients, all of which were HIV-positive. Some of those participating in the trial received a placebo.

The researchers say data from the trial is still being analysed, but say the results they have been able to gather show “significant increase in the HIV-1 antibody formations after SAV001-H administration compared to the base line in some patients.”

That result, along with the lack of adverse effects, sees the researchers declare “we are now prepared to take the next steps towards Phase II and Phase III clinical trials” among a wider population.

The vaccine is described as a a “killed whole virus”, a type of vaccine that uses a genetically-engineered version of the HIV virus that is subjected to chemicals and radiation in ways that allow it to fight HIV without hurting the patient. Such vaccines are already used to treat polio, rabies, influenza and other diseases.

There's still a long way to go before SAV001-H becomes widely available. As the USA's national Institutes of Health explains, Phase II trials use a larger sample to test whether a drug “is effective and to further evaluate its safety” while Phase III trials work with more people again to test “effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.” ®

Top three mobile application threats

More from The Register

next story
Red-faced LOHAN team 'fesses up in blown SPEARS fuse fiasco
Standing in the corner, big pointy 'D' hats
KILLER SPONGES menacing California coastline
Surfers are safe, crustaceans less so
LOHAN's Punch and Judy show relaunches Thursday
Weather looking good for second pop at test flights
Discovery time for 200m WONDER MATERIALS shaved from 4 MILLENNIA... to 4 years
Alloy, Alloy: Boffins in speed-classification breakthrough
Curiosity finds not-very-Australian-shaped rock on Mars
File under 'messianic pastries' and move on, people
Elon Musk's LEAKY THRUSTER gas stalls Space Station supply run
Helium seeps from Falcon 9 first stage, delays new legs for NASA robonaut
Top Secret US payload launched into space successfully
Clandestine NRO spacecraft sets off on its unknown mission
New FEMTO-MOON sighted BIRTHING from Saturn's RING
Icy 'Peggy' looks to be leaving the outer rings
Melting permafrost switches to nasty, high-gear methane release
Result? 'Way more carbon being released into the atmosphere as methane'
prev story

Whitepapers

Designing a defence for mobile apps
In this whitepaper learn the various considerations for defending mobile applications; from the mobile application architecture itself to the myriad testing technologies needed to properly assess mobile applications risk.
3 Big data security analytics techniques
Applying these Big Data security analytics techniques can help you make your business safer by detecting attacks early, before significant damage is done.
Five 3D headsets to be won!
We were so impressed by the Durovis Dive headset we’ve asked the company to give some away to Reg readers.
The benefits of software based PBX
Why you should break free from your proprietary PBX and how to leverage your existing server hardware.
Securing web applications made simple and scalable
In this whitepaper learn how automated security testing can provide a simple and scalable way to protect your web applications.